Clinical Trial Search

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Response Rate (Per RECIST 1.1) — 1 Participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Tumor Response — 0 percentage of participants

Primary: Overall Survival (OS) — 13.73; 13.14 Months

Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants

Primary: The Objective Response Rate (ORR) Based on RECIST 1.1 — 6 Participants

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: 12-week Progression Free Rate — 68.29 percentage of participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Number of Participants Who Were Progression Free — 12 Participants

Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…

Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Progression-Free Survival — 2.64; 1.38 months

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001

Primary: Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory — -2.50; -1.26 units on a scale

Primary: Number of Participants With Serious Adverse Events — 0; 0 Participants

Primary: 6-month Progression-free Survival Rate (PFS) — 12 participants

Primary: Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses — 48.7; 60.5 percentage of subjects

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)